Successfully reported this slideshow.
Your SlideShare is downloading. ×

Antimicrbial agent 3 (2).ppt

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Upcoming SlideShare
Antibiotics
Antibiotics
Loading in …3
×

Check these out next

1 of 53 Ad

More Related Content

Similar to Antimicrbial agent 3 (2).ppt (20)

Advertisement

Recently uploaded (20)

Antimicrbial agent 3 (2).ppt

  1. 1. Ministry Of Higher Education & Scientific Research Alzaiem Alazhari University, Sudan Faculty of Medical Laboratory Sciences (MLS) 8 February 2023 1
  2. 2. Antimicrobial agents and Chemotherapy Prepared by: Mohamed Ahmed Ibrahim Holie AL-ZAIEM ALA-zhari University Faculty of Medical Laboratory Sciences Holie2330@yahoo.com 8 February 2023 2
  3. 3. Definitions of Antibiotics • OLD: An antibiotic is a chemical substance produced by various species of microorganisms that is capable in small concentrations of inhibiting the growth of other microorganisms • NEW: An antibiotic is a product produced by a microorganism or a similar substance produced wholly or partially by chemical synthesis, which in low concentrations, inhibits the growth of other microorganisms 8 February 2023 3
  4. 4. Disadvantages from taking medication without doctor guide  Emergency of Resistance.  Drug toxicity.  Cost.  Drug dose.  Interaction of the drug with other disease.  Susceptibility of the pathogenes to the drug.  Time consuming. 8 February 2023 4
  5. 5. Antimicrobial agents:  Chemical and therapeutic agents that acts against bacteria, viruses, fungi and parasite.  Antibiotic ------ Natural product from microorganism.  Chemotherapy ------ Chemically synthetic or semi synthetic agent. 8 February 2023 5
  6. 6. 6  Antibacterials can be classified into: a. By their activity level action: 1. Bacteriostatic: they arrest the growth & replication of bacteria e.g. Sulfonamides, Chloramphenicol 2. Bactericidal: kills the bacteria e.g. Penicillins 8 February 2023
  7. 7. 7 b. Spectrum of activity: 1. extended spectrum of antibiotic: active against types of bacteria G- & G+ 2. Narrow spectrum antibiotic: active against single or limited # of M.O 3.broad spectrum: active against a wide variety of microbial species 8 February 2023
  8. 8. 8 Combination of antimicrobials Advantages: 1. Delay the development of resistance. 2. To broaden the spectrum of activity. 3. Potentiation of action of one another. indifferent Combination of antibiotics either synergism antagonism A 60% bacterial inhibition A+B 80% synergism A+C 40% antagonism A+D 60% indifferent 8 February 2023
  9. 9. 9 Prophylaxis antibiotics:  Definition A prophylaxis is a measure taken to maintain health and prevent the spread of disease. Antibiotic prophylaxis is refers to the use of antibiotics to prevent infections as: 1.Treatment prior to surgical procedures as bowel surgery, joint replacement to prevent infection. 2.prevention of tuberculosis or meningitis in individuals who are close contact with infected patients. 8 February 2023
  10. 10. 10 3. Suppression of existing infection before it cause a disease, e.g. animal bite. 4. Prevention of streptococcal infection in patients with history of rheumatic heart disease. 5. prevention of opportunistic infection →infective endocarditis. 8 February 2023
  11. 11. By their Mechanisms of Action Antibacterials can be classified into:  Inhibition of cell wall synthesis.  Inhibition of Cell membrane synthesis.  Inhibition of protein synthesis.  Inhibition of Nucleic acid synthesis.  Metabolic antagonism. 8 February 2023 11
  12. 12. Inhibition of cell wall synthesis:  -Lactam containing antimicrobial:  Penicillin.  Ampicillin.  Amoxicillin.  Amoxicillin-clavulinic acid.  Cephalosporins:  1st generation (Cephalothin, Cephapirin, Cephazolin, Cephalexin, Cephradine, and Cefadroxil). 8 February 2023 12
  13. 13.  2nd generation: (Cefoxitin, Cefotetan, Cefamandole, Cefuroxime, Cefonicid, Cefaclor, Cefprozil, Cefmetazole).  3rd generation: (Cefotaxime, Ceftizoxime, Ceftriaxone, Ceftazidime, Cefoperazone, Cefixime, Ceftibuten).  4th generation: (Cefepim).  Bacitracin.  Vancomycin. 8 February 2023 13
  14. 14. 1. -Lactam containing Antibiotics Penicillin:  From Penicillium notatum.  Discovered at 1928 and used at 1938.  Active part is β-lactam ring.  Inter through penicillin binding proteins.  Resistant by:  Production of β-lactamase.  Lack or alteration of PBPs.  Failure in activation of autolytic enzyme.  Failure in synthesis of peptidoglycan (Mycoplasma).  Side effect:  Penicillin allergy.  Types:  Penicillin G Acid sensitive (IV and IM).  Penicillin V Acid Resistant (Oral) 8 February 2023 14
  15. 15.  Ampicillin:  Broad spectrum antimicrobial (G+ve and some G-ve).  Acid tollerant.  Amoxicillin:  Have wide range of activity against G+ve G-ve and some Anaerobe)  Could be taken orally.  Amoxicillin-Clavulinic acid (Augmentin or Amoclan):  More penicillinase resistant antimicrobial  Monobactam:  IV or IM antimicrobial that active against G-ve bacteria and resist β- lactamase (e.g.: Aztreonam).  Carpenems:  Active against G+ve and G-ve bacteria and anaerobes except bacteroides.  Could reach CSF.  Side effects:  Skin rash, diarrhoea, vomiting, and Hypersensitivity. 8 February 2023 15
  16. 16. Cephalosporins:  Same as penicillin in action.  Resistance:  Poor permeation of bacteria (No entry).  Lack or alteration of PBPs.  β-lactamase production.  Side effects:  Hypersensitivity.  Thrombocytopenia.  1st generation:  Active against G+ve cocci except enterococci, moderate active against E.coli, Klebsiella, proteus and some anaerobic.  Cephalexin and Cephradin given orally.  Could be used in UTI and RTI.  Cephalexin used as post operative prophylaxis. 8 February 2023 16
  17. 17.  2nd generation:  Active against G+ve and G-ve (except pseudomonas) and some anaerobe.  3rd generation:  Less active against G+ve, but active against G-ve and moderate action against pseudomonas.  Have the ability to reach the CSF.  4th generation:  Act against G-ve including enterobacter and Citrobacter Pseudomonas and moderate sensitive against G+ve. 8 February 2023 17
  18. 18. 2. Bacitracin:  From B. subtilus.  Inhibit early cell wall synthesis in cell membrane (inhibit lipid carrier).  Poor absorbance from GIT.  Very active against G+ve bacteria.  Used as ointment.  Side effect:  Kidney damage.  Nitrogen retention. 8 February 2023 18
  19. 19. 3. Vancomycin:  From S. orientalis  Bind with peptide chain inhibiting transpeptidation.  Side effects:  Skin rash.  Kidney damage. 8 February 2023 19
  20. 20. Inhibition of cell membrane:  Polymexin B:  Disrupt plasma membrane structure.  Bacteriocidal for G-ve and G+ve.  High toxic used as Ointment.  Side effects:  Nephrotoxic.  Neurotoxic. 8 February 2023 20
  21. 21. Inhibition of Protein synthesis:  Inhibition of 30 S rRNA:  Aminoglycoside.  Tetracyclins  Inhibition of 50 S rRNA:  Chloramphenicol.  Lincosamide (Lincomycin and clindamycin).  Macrolides (Erythromycin, Clarithromycin).  Fusidic acid Affect Elongation factor G. 8 February 2023 21
  22. 22. Aminoglycoside:  Streptomycin, Neomycin, Kanamycin, Amikacin, Gentamicin, and tobramycin.  Bacteriostatic inhibit 30 S rRNA.  Active at alkaline PH.  Broad spectrum (G+ve and G-ve and Mycobacterium).  Give synergistic effect with penicillin.  In blood culture aminoglycoside inhibited by Na polyanithol sulfonate.  Resistance by:  Deficiency in Ribosomal receptor.  Lack of permeability to the drug (transportation is oxygen dependent).  Side effect:  Nephrotoxic and Ototoxic. 8 February 2023 22
  23. 23. Doxycyclins and Tetracyclins:  Inhibit G+ve, G-ve, Rickettsia, Chlamydia, Mycoplasma, Brucella, Yersinea and Vibreo.  Bacteriostatic in action.  Have poor penetration to CSF.  Side effects:  Gastrointestinal upset (Nausea, Vomiting, and Diarrhoea).  Skin rash.  Deposition in bone structures and teeth particularly in fetus. 8 February 2023 23
  24. 24. Chloramphenicol:  From S. vensuelae (Now synthesized).  Wide distributed in all body fluid including CSF.  Inactivated in liver and secreted in urine in inactive form.  Bacteriostatic in action.  Resistant by production of Chloramphenicol acetyl transferase.  Side effects:  GIT upset.  Aplastic anaemia.  Gray fetal syndrome. (Have no develop liver so No inactivation). 8 February 2023 24
  25. 25. Lincosamide (Lincomycin and Clindamycin):  From S. licolnsis.  Very active against bacteroides and other anaerobes.  Cause Pseudomembranous colitis.  Acid stable.  Cold not penetrate CSF. 8 February 2023 25
  26. 26. Macrolides (Erythromycin, azithromycin and Clarythromycin):  From S. erythrus.  Resistance by alteration of rRNA receptor.  Active at alkaline PH.  Active at G+ve, G-ve, Chlamydia, Mycoplasma and Legionella.  Side effects:  GIT upset.  Fever.  Affect liver cells causing hepatitis. 8 February 2023 26
  27. 27. Quinolones:  Block DNA gyrase.  E.g.: Nalidixic acid, Oxolinic acid, Ciprofloxacin, Ofloxacin, Norfloxacin, Pefloxacin, and Nitrofurantoin.  Used in UTI.  Active against G-ve, G+ve, Haemophilus, Pseudomonas and Mycobacterium.  Side effect:  Nausea, headache, and dizziness.  Skin rash.  Impaired liver function. Inhibition of Nucleic acid: 8 February 2023 27
  28. 28. Rifampin:  Active against some G+ve, G-ve, Enteric cocci, Mycobacterium, Chlamydia and pox virus.  Bind with RNA polymerase (inhibit RNA synthesis).  Could penetrate inside phagocytic cells.  Side effects:  Orange pigment in urine and sweat.  Skin rash.  Thrombocytopenia.  Impaired liver function. 8 February 2023 28
  29. 29. Metabolic antagonistic:  Bacteriostatic for some G+ve and G-ve bacteria.  Inhibit folic acid synthesis.  Synergistic effect obtained from Cotrimoxazole (Trimethoprim and Sulphomethoxazole).  Side effects:  Hypersensitivity.  Fever and skin rash.  GIT disturbances.  Depression of bone marrow.  Liver and kidney function abnormality. Sulphonamide and trimethoprim: 8 February 2023 29
  30. 30. Antimicrobial susceptibility pattern:  Kirby Bauer agar disk diffusion methods:  Aim:  To perform standard sensitivity test on agar media.  Test requirements:  Media: Muller & Hinton agar and Broth media  Antimicrobial disks: Multi or single disks  STD turbidity tube: McForland tube (Bacl2 + H2So4)  Pure culture from organism under test. 8 February 2023 30
  31. 31. Standard MacForland tubes 8 February 2023 31
  32. 32. Disk dispenser 8 February 2023 32
  33. 33.  Test Procedure:  Make a suspension by touching more than 10 colonies and emulsify on M&H broth.  Incubate for 30 min in water bath.  Compare the turbidity with 0.5 McForland tube (contain 0.05 ml of 1.16% Bacl2 + 9.95 ml of 1% H2SO4).  Streak on M&H agar using Ca++ alignment swab 3 times inverting the plate 60 each time.  For H influenzae, S. pneumoniae, and Neisseria we use M&H supplemented with Heated sheep Blood and for Streptococci we use Blood agar.  Put the disk on the center of the plate allowing 1.5 cm distances from the edge of the plate and 1 cm between each disks (the plate take about 8 disks).  Incubate at 37C for exactly 18 hours.  Read the diameter of the disk using ruler and compare it with a STD.  Report your results as HS, MS, SS, R. 8 February 2023 33
  34. 34. 8 February 2023 34
  35. 35. 8 February 2023 35
  36. 36. 8 February 2023 36
  37. 37. Antagonism 8 February 2023 37
  38. 38. Agar diffusion for fastidious microorgnisms 8 February 2023 38
  39. 39. 8 February 2023 39
  40. 40. Same plate comparative methods (Stoke)  We culture control strain on the center of the plate and tested organism on the two edges. Put the disks between. 8 February 2023 40
  41. 41. Dilution methods:  This used to detect antimicrobial susceptibility to slow growing M.O and anaerobic.  It could be carried out on Microtiter plate or test tube.  Also it used to detect MIC to antimicrobials  We make serial dilution of antimicrobials and add 5 drops from 106 bacterial suspension and incubate at 37 C, then read about turbidity which indicate resistance and clearance which indicate sensitivity, and detect the MIC. 8 February 2023 41
  42. 42. Tube dilution method 8 February 2023 42
  43. 43. Factors affect antimicrobial agar disk diffusion method:  Type of the medium.  Depth of the medium (4 mm)  Surface of the medium  Supplement in the medium (mg and ca) and Blood  Moisture of the medium  pH of the medium  Source and expiry date of antimicrobial agents  Concentration of antimicrobials in the disk  Distribution of disks on the surface of the medim.  Nature of organism  Inoculum size.  Incubation temperature.  Incubation condition.  Incubation time. 8 February 2023 43
  44. 44. Microdilution methods 8 February 2023 44
  45. 45. 8 February 2023 45
  46. 46. Epsiloid test (E test):  Used for detection of MIC in plate procedure.  We could detect more than one MIC at the same time. 8 February 2023 46
  47. 47. E. Test 8 February 2023 47
  48. 48. 8 February 2023 48
  49. 49. Antimicrobial Resistant test:  β lactamase test:  Cefinase β lactamase disk:  Using disks contain nitrocefin, we add suspension of Microorganism and see the development of Pink-Brown color within 10 min indicating β lactamase production.  Acidimetric technique:  Using citrate buffered penicillin and phenol red. Penicillin destroyed by the enzyme to give penicilloic acid which change the color from red into yellow.  Iodometric technique:  Using phosphate buffered penicillin and starch-iodine complex, penicilloic acid prevent binding of starch with penicillin which convert the color from blue to colorless. 8 February 2023 49
  50. 50. Errors of reading 8 February 2023 50
  51. 51. Yeast 8 February 2023 51
  52. 52. Beta lactamase detection 8 February 2023 52
  53. 53. 8 February 2023 53

×